

Availability of the Universal Registration Document Universal Registration Document (URD) 2022

Aix-en-Provence, April 26, 2023 - 8:00 pm CET- Affluent Medical (ISIN code: FR0013333077 – ticker: AFME), a French MedTech specializing in the international development and industrialization of innovative medical prostheses, at a clinical stage, to treat mitral heart valve pathology and urinary incontinence, announces today the availability to the public of its 2022 Universal Registration Document (URD), filed with the Autorité des marchés financiers (AMF) on April 26, 2023, under visa number R.23-019.

This document, which is available to the public free of charge under the conditions provided for by the regulations in force, can be consulted on the company's website www.affluentmedical.com (Investor Relations/Financial Documentation), as well as on that of the AMF (www.amf-france.org).

The 2022 Universal Registration Document has been prepared in the European Single Electronic Format (ESEF) in XBRL and includes:

- the 2022 annual financial report, consisting of the management report, the corporate governance report and the parent company and consolidated financial statements for the year ended December 31, 2022;
- the statutory auditors' reports and information on their fees;
- a description of the share buyback program.

An English version of the 2022 Universal Registration Document will be made available shortly.



About Affluent Medical

Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary incontinence which currently affects one in four adults.

Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions. The product candidates developed by the Company are currently in preclinical and clinical studies.

Kalios™, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed. Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies, the Company's ambition is to progressively commercialize its products starting in 2025.

For more information: www.affluentmedical.com

Contacts:

AFFLUENT MEDICAL

Sébastien LADET
Chief Executive Officer
investor@affluentmedical.com

ACTIFIN, financial communications

Ghislaine GASPARETTO
+33 (0)6 21 10 49 24
affluentmedical@actifin.fr

ACTIFIN, financial press relations

Jennifer JULLIA
+33 (0)1 56 88 11 19
jjullia@actifin.fr

PRIMATICE, public relations France

Thomas ROBOREL de CLIMENS
+33 (0)6 78 12 97 95
thomasdeclimens@primatice.com